Abstract
Nonsyndromic orofacial clefts (OFCs) are common, heritable birth defects caused by both genetic and environmental risk factors. Despite the identification of many genetic loci harboring OFC-risk variants, there are many unknown genetic determinants of OFC. Furthermore, while the process of embryonic facial development is well characterized, the molecular mechanisms that underly it are not. This represents a major hurdle in understanding how disruptions in these biological processes result in OFC. Thus, we sought to identify novel OFC-risk loci through a genome-wide multi-ancestry study of five nested OFC phenotypes (isolated cleft lip [CLO], isolated cleft palate [CPO], cleft lip and palate [CLP], cleft lip with/without cleft palate [CL/P], and any cleft [ANY]) representing distinct cleft subtypes to identify subtype-specific signals and grouped types to maximize power to detect shared genetic effects. We performed genome-wide meta-analyses of these five OFC phenotypes from three cohorts totaling >14,000 individuals using METAL. In addition to replicating 13 known OFC-risk loci, we observed novel association in three regions: the 1p36.32 locus (lead variant rs584402, an intergenic variant, pCLO = 3.14e-8), the 7q33 locus (lead variant rs17168118, an intronic variant in CALD1, pCLP = 9.17e-9), and the 16p13.3 locus (lead variant rs77075754, an intronic variant in RBFOX1, pCL/P = 1.53e-9, pANY = 1.93e-9). We also observed a novel association within the known risk locus 8q22.1 that was independent of the previously reported signal (lead variant rs4735314, an intronic variant in ESRP1, pCLP = 1.07e-9, pCL/P = 3.88e-8). Next, we performed multi-tissue TWAS with s-MulTiXcan and identified four overlapping genes with significant genetically predicted transcription associated with OFC risk. These genes also overlapped the genome-wide significant association signals from the meta-analysis, including CALD1 and ESRP1 and known OFC-risk genes TANC2 and NTN1. Each of the newly reported loci has potential regulatory effects, including evidence of craniofacial enhancer activity, that offer new clues as to the molecule mechanisms underlying embryonic facial development.
Author Summary Orofacial clefts, including cleft lip and cleft palate, are common birth defects that can be caused by both genetic and environmental factors. While many of these factors are known, there are still significant gaps in our understanding of how and why clefts arise. To help address this deficiency, we measured association between variants across the genome and clefting in cases and controls from diverse genetic ancestries. We identified three new candidate genes (CALD1, ESRP1, and RBFOX1) that may be involved in cleft risk and reaffirmed the role of 12 previously reported risk genes. We also found evidence that clefting was associated with predicted gene expression at CALD1 and ESRP1 and that the associated variants in these genes were located near regions known to be involved in the regulation of gene expression in craniofacial tissues during development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by grants from the National Institutes of Health (NIH, https://www.nih.gov/): R01-DE016148 (MLM, SMW), R01-DE032122 (JRS), U01-DE018993 (THB), X01-HG00784 (MLM), X01-HG011437 (JRS, MLM), R01-DE08559 (JCM), T90-DE030853 (ZE, PI: C Spier), R01-DE032332 (EJL, PI: E Liao), R01-DE032319 (MLM), R01-DE030342 (EJL), R01-DE027362 (EJL, PI: R Cornell). This research was also supported in part by the University of Pittsburgh Center for Research Computing, RRID:SCR_022735, through the resources provided. Specifically, this work used the HTC cluster, which is supported by NIH award number S10OD028483. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was given for the coordinating site and the recruitment sites from which data in this study were generated from the following institutions. USA: The University of Pittsburgh Institutional Review Board, FWA00006790, Coordinating Site and PA sites approval; The University of Iowa Institutional Review Board, FWA00003007, IA sites approval; University of Texas Houston Health Sciences IRB, FWA00000667; University of Puerto Rico, Medical Sciences Ethical Committee, FWA00005561. COLOMBIA: Ethics Committee of Fundacion Clinica Noel de Medellin. ARGENTINA: ECLAMC/CEMIC Ethics Committees, Buenos Aires, Argentina, FWA0001566 and FWA00001745. GUATEMALA: Ethics Committes of the Hospital Nacional de Huehuetenango and Hospital Nacional Tiquisate, Guatemala. HUNGARY: GAT Foundation Budapest, Hungary, FWA0001328. NIGERIA: Lagos University Teaching Hospital, Health Research Ethics Committee, Lagos, Nigeria. THE PHILIPPINES: University of the Philippines, Manila, Ethics Committee FWA00003505.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos